Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 36367476)

  • 1. pH-responsive nanoprodrugs combining a Src inhibitor and chemotherapy to potentiate antitumor immunity via pyroptosis in head and neck cancer.
    Zhu SW; Ye M; Ma X; Wu ZZ; Wan SC; Yang SC; Li H; Xu Z; Sun ZJ
    Acta Biomater; 2022 Dec; 154():497-509. PubMed ID: 36367476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneously inactivating Src and AKT by saracatinib/capivasertib co-delivery nanoparticles to improve the efficacy of anti-Src therapy in head and neck squamous cell carcinoma.
    Lang L; Shay C; Zhao X; Xiong Y; Wang X; Teng Y
    J Hematol Oncol; 2019 Dec; 12(1):132. PubMed ID: 31805962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of cisplatin-resistant head and neck squamous cell carcinoma by the SRC/ETS-1 signaling pathway.
    Yang Z; Liao J; Carter-Cooper BA; Lapidus RG; Cullen KJ; Dan H
    BMC Cancer; 2019 May; 19(1):485. PubMed ID: 31118072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cisplatin and oxaliplatin induce similar immunogenic changes in preclinical models of head and neck cancer.
    Park SJ; Ye W; Xiao R; Silvin C; Padget M; Hodge JW; Van Waes C; Schmitt NC
    Oral Oncol; 2019 Aug; 95():127-135. PubMed ID: 31345380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of SRC family kinases facilitates anti-CTLA4 immunotherapy in head and neck squamous cell carcinoma.
    Yu GT; Mao L; Wu L; Deng WW; Bu LL; Liu JF; Chen L; Yang LL; Wu H; Zhang WF; Sun ZJ
    Cell Mol Life Sci; 2018 Nov; 75(22):4223-4234. PubMed ID: 29955905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of SRC family kinases reduces myeloid-derived suppressor cells in head and neck cancer.
    Mao L; Deng WW; Yu GT; Bu LL; Liu JF; Ma SR; Wu L; Kulkarni AB; Zhang WF; Sun ZJ
    Int J Cancer; 2017 Mar; 140(5):1173-1185. PubMed ID: 27798955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paclitaxel-loaded polymeric nanoparticles based on α-tocopheryl succinate for the treatment of head and neck squamous cell carcinoma:
    Riestra-Ayora J; Sánchez-Rodríguez C; Palao-Suay R; Yanes-Díaz J; Martín-Hita A; Aguilar MR; Sanz-Fernández R
    Drug Deliv; 2021 Dec; 28(1):1376-1388. PubMed ID: 34180747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting DDR2 in head and neck squamous cell carcinoma with dasatinib.
    von Mässenhausen A; Sanders C; Brägelmann J; Konantz M; Queisser A; Vogel W; Kristiansen G; Duensing S; Schröck A; Bootz F; Brossart P; Kirfel J; Lengerke C; Perner S
    Int J Cancer; 2016 Nov; 139(10):2359-69. PubMed ID: 27434411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IGF1R and Src inhibition induce synergistic cytotoxicity in HNSCC through inhibition of FAK.
    Lehman CE; Spencer A; Hall S; Shaw JJP; Wulfkuhle J; Petricoin EF; Bekiranov S; Jameson MJ; Gioeli D
    Sci Rep; 2021 May; 11(1):10826. PubMed ID: 34031486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor pH-functionalized and charge-tunable nanoparticles for the nucleus/cytoplasm-directed delivery of oxaliplatin and miRNA in the treatment of head and neck cancer.
    Lo YL; Lin HC; Tseng WH
    Acta Biomater; 2022 Nov; 153():465-480. PubMed ID: 36115656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells.
    Johnson FM; Saigal B; Talpaz M; Donato NJ
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6924-32. PubMed ID: 16203784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overcoming chemotherapy resistance using pH-sensitive hollow MnO
    Zhou ZH; Liang SY; Zhao TC; Chen XZ; Cao XK; Qi M; Huang YY; Ju WT; Yang M; Zhu DW; Pang YC; Zhong LP
    J Nanobiotechnology; 2021 May; 19(1):157. PubMed ID: 34039370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CXCR4-targeted nanotoxins induce GSDME-dependent pyroptosis in head and neck squamous cell carcinoma.
    Rioja-Blanco E; Arroyo-Solera I; Álamo P; Casanova I; Gallardo A; Unzueta U; Serna N; Sánchez-García L; Quer M; Villaverde A; Vázquez E; León X; Alba-Castellón L; Mangues R
    J Exp Clin Cancer Res; 2022 Feb; 41(1):49. PubMed ID: 35120582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-1 alpha increases anti-tumor efficacy of cetuximab in head and neck squamous cell carcinoma.
    Espinosa-Cotton M; Rodman Iii SN; Ross KA; Jensen IJ; Sangodeyi-Miller K; McLaren AJ; Dahl RA; Gibson-Corley KN; Koch AT; Fu YX; Badovinac VP; Laux D; Narasimhan B; Simons AL
    J Immunother Cancer; 2019 Mar; 7(1):79. PubMed ID: 30890189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Src family kinase targeting in head and neck tumor cells using SU6656, PP2 and dasatinib.
    Vu AT; Akingunsade L; Hoffer K; Petersen C; Betz CS; Rothkamm K; Rieckmann T; Bussmann L; Kriegs M
    Head Neck; 2023 Jan; 45(1):147-155. PubMed ID: 36285353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microenvironment-Responsive Prodrug-Induced Pyroptosis Boosts Cancer Immunotherapy.
    Xiao Y; Zhang T; Ma X; Yang QC; Yang LL; Yang SC; Liang M; Xu Z; Sun ZJ
    Adv Sci (Weinh); 2021 Dec; 8(24):e2101840. PubMed ID: 34705343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metformin sensitizes anticancer effect of dasatinib in head and neck squamous cell carcinoma cells through AMPK-dependent ER stress.
    Lin YC; Wu MH; Wei TT; Lin YC; Huang WC; Huang LY; Lin YT; Chen CC
    Oncotarget; 2014 Jan; 5(1):298-308. PubMed ID: 24457597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liposomal oxaliplatin prodrugs loaded with metformin potentiate immunotherapy for colorectal cancer.
    Song L; Hao Y; Wang C; Han Y; Zhu Y; Feng L; Miao L; Liu Z
    J Control Release; 2022 Oct; 350():922-932. PubMed ID: 36108810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dasatinib blocks cetuximab- and radiation-induced nuclear translocation of the epidermal growth factor receptor in head and neck squamous cell carcinoma.
    Li C; Iida M; Dunn EF; Wheeler DL
    Radiother Oncol; 2010 Nov; 97(2):330-7. PubMed ID: 20667610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HSP90 inhibition suppresses tumor glycolytic flux to potentiate the therapeutic efficacy of radiotherapy for head and neck cancer.
    Chen F; Tang C; Yang F; Ekpenyong A; Qin R; Xie J; Momen-Heravi F; Saba NF; Teng Y
    Sci Adv; 2024 Feb; 10(8):eadk3663. PubMed ID: 38394204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.